Become a DETERMINE partner

The DETERMINE trial enables the valuation of licensed targeted cancer drugs in unlicensed cancer indications. We are seeking additional licensed targeted drugs from pharmaceutical and biotech companies and welcome enquiries about being included in the study.  

The trial is expected to recruit for 5 years with a 2-year follow-up period. Treatment arms will be added on a continual basis, with each arm to be evaluated through regular interim analyses. 

As a commercial partner, you’ll benefit from:  

• evaluation of novel, fast-track route to approval via the Cancer Drugs Fund (CDF) for drugs which prove effective  
• rich translational data package that can help optimise biomarker selection of patients  
• streamlined compassionate use requests into a structured access mechanism with associated data collection  
• dedicated Business Development contact and single contract to gain access to a trial with over 20 sites

Submit your partnering enquiry

Explore our latest announcements

To enter the DETERMINE trial, drugs must target a genomic aberration detectable by genetic screening, be licensed in a major market (eg MHRA, FDA, EMA), and have a UK/EU-compliant drug supply mechanism. 

Current treatment arms 

There are currently seven agents available across five arms in the DETERMINE trial, each targeting a specific genomic profile: 

1. Alectinib (Alecensa) 
2. Atezolizumab (Tecentriq) 
3. Entrectinib (Rozlytrek) 
4. Trastuzumab (Herceptin) and Pertuzumab (Perjeta) 
5. Vemurafenib (Zelboraf) and Cobimetinib (Cotellic) 
6. Capmatinib (Tabrecta)

Recruitment and delivery

The trial aims to recruit 350–400 patients, through existing national screening programmes over the five-year recruitment period. 

DETERMINE is delivered through the Experimental Cancer Medicine Centres Network, which consists of 29 adult and paediatric sites across the UK.

As the trial sponsor, the Cancer Research UK Centre for Drug Development is responsible for all aspects of management and delivery of DETERMINE, acting as the central contact point for our partners.